WO2008093688A1 - キメラFcγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法 - Google Patents

キメラFcγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法 Download PDF

Info

Publication number
WO2008093688A1
WO2008093688A1 PCT/JP2008/051333 JP2008051333W WO2008093688A1 WO 2008093688 A1 WO2008093688 A1 WO 2008093688A1 JP 2008051333 W JP2008051333 W JP 2008051333W WO 2008093688 A1 WO2008093688 A1 WO 2008093688A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
chimeric
fcγ
adcc activity
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/051333
Other languages
English (en)
French (fr)
Inventor
Shigeto Kawai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Forerunner Pharma Research Co Ltd
Original Assignee
Forerunner Pharma Research Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forerunner Pharma Research Co Ltd filed Critical Forerunner Pharma Research Co Ltd
Priority to US12/525,031 priority Critical patent/US8946385B2/en
Priority to AT08704115T priority patent/ATE504647T1/de
Priority to DE602008006041T priority patent/DE602008006041D1/de
Priority to JP2008556119A priority patent/JP5299902B2/ja
Priority to EP08704115A priority patent/EP2123754B1/en
Publication of WO2008093688A1 publication Critical patent/WO2008093688A1/ja
Anticipated expiration legal-status Critical
Priority to US14/556,684 priority patent/US9733245B2/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

　本発明は、マウスFcγレセプター細胞外領域とヒトFcγレセプター膜貫通領域を含むキメラレセプター、またはマウスFcγレセプター細胞外領域とヒトγ鎖膜貫通領域を含むキメラレセプターを提供することを課題とする。又、本発明は該キメラレセプターを用いたマウス抗体のADCC活性を測定する為の方法、ADCC活性を有するマウス抗体のスクリーニング方法を提供することを課題とする。 　本発明者らは、上記の課題を解決するために、マウスFcγR3あるいはマウスFcγR4の細胞外領域と、ヒトγ鎖あるいはヒトFcγR3の膜貫通領域－細胞内領域を融合したキメラ分子を作製し、ヒトNK92細胞に発現させた。その結果、いずれの組み合わせのキメラレセプターでもADCC活性を誘導しうることが見出され、本発明のキメラレセプターにより、マウス抗体のADCC活性を測定することが可能であることを見出した。
PCT/JP2008/051333 2007-01-30 2008-01-30 キメラFcγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法 Ceased WO2008093688A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/525,031 US8946385B2 (en) 2007-01-30 2008-01-30 Chimeric Fcγ receptor and method for determination of ADCC activity by using the receptor
AT08704115T ATE504647T1 (de) 2007-01-30 2008-01-30 Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors
DE602008006041T DE602008006041D1 (de) 2007-01-30 2008-01-30 CHIMÄRER Fc GAMMA REZEPTOR UND VERFAHREN ZUR BESTIMMUNG VON ADCC-AKTIVITÄT UNTER VERWENDUNG DES REZEPTORS
JP2008556119A JP5299902B2 (ja) 2007-01-30 2008-01-30 キメラＦｃγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法
EP08704115A EP2123754B1 (en) 2007-01-30 2008-01-30 CHIMERIC Fc GAMMA RECEPTOR AND METHOD FOR DETERMINATION OF ADCC ACTIVITY BY USING THE RECEPTOR
US14/556,684 US9733245B2 (en) 2007-01-30 2014-12-01 Chimeric Fc-gamma receptor and method for determination of ADCC activity by using the receptor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-020155 2007-01-30
JP2007020155 2007-01-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/525,031 A-371-Of-International US8946385B2 (en) 2007-01-30 2008-01-30 Chimeric Fcγ receptor and method for determination of ADCC activity by using the receptor
US14/556,684 Division US9733245B2 (en) 2007-01-30 2014-12-01 Chimeric Fc-gamma receptor and method for determination of ADCC activity by using the receptor

Publications (1)

Publication Number Publication Date
WO2008093688A1 true WO2008093688A1 (ja) 2008-08-07

Family

ID=39673997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/051333 Ceased WO2008093688A1 (ja) 2007-01-30 2008-01-30 キメラFcγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法

Country Status (6)

Country Link
US (2) US8946385B2 (ja)
EP (1) EP2123754B1 (ja)
JP (1) JP5299902B2 (ja)
AT (1) ATE504647T1 (ja)
DE (1) DE602008006041D1 (ja)
WO (1) WO2008093688A1 (ja)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074049A1 (ja) 2008-12-22 2010-07-01 株式会社 未来創薬研究所 抗hs6st2抗体及びその用途
WO2010074192A1 (ja) 2008-12-26 2010-07-01 国立大学法人東京大学 抗lgr7抗体を用いる癌の診断および治療
WO2010073694A1 (ja) 2008-12-25 2010-07-01 国立大学法人東京大学 抗tm4sf20抗体を用いた癌の診断と治療
WO2011093097A1 (ja) 2010-01-29 2011-08-04 株式会社未来創薬研究所 抗dll3抗体
WO2012144208A1 (ja) 2011-04-18 2012-10-26 国立大学法人東京大学 抗itm2a抗体を用いる癌の診断および治療
WO2013147153A1 (ja) 2012-03-29 2013-10-03 株式会社未来創薬研究所 抗ｌａｍｐ５抗体およびその利用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
ATE504647T1 (de) 2007-01-30 2011-04-15 Forerunner Pharma Res Co Ltd Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors
EP4541818A3 (en) * 2012-05-25 2025-07-23 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
AU2015204729A1 (en) * 2014-01-08 2016-07-21 1Globe Biomedical Co., Ltd. Novel synthetic biology-based ADCC technology
RU2700484C2 (ru) * 2014-04-08 2019-09-17 Регенерон Фармасьютикалз, Инк. Не относящиеся к человеку животные, имеющие гуманизированные fc-гамма-рецепторы
CN107709552B (zh) * 2015-06-10 2022-05-13 南克维斯特公司 用于治疗癌症的修饰的nk-92细胞
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
JP7339325B2 (ja) * 2018-03-20 2023-09-05 ナショナル ヘルス リサーチ インスティテューツ 単離抗体、医薬組成物、単離抗体結合体、ダイマー化阻害方法、シグナル伝達阻害方法、管新生阻害方法、治療方法、および断片検出方法
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
TW202237827A (zh) 2020-12-03 2022-10-01 美商世紀治療股份有限公司 經基因工程改造之細胞及其用途
US11661459B2 (en) 2020-12-03 2023-05-30 Century Therapeutics, Inc. Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
WO2023114847A2 (en) * 2021-12-14 2023-06-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1998013388A1 (en) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
JP2004147565A (ja) * 2002-10-30 2004-05-27 Japan Science & Technology Agency 不死化ナチュラルキラー細胞株
WO2006067913A1 (ja) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE504647T1 (de) 2007-01-30 2011-04-15 Forerunner Pharma Res Co Ltd Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239400A2 (en) 1986-03-27 1987-09-30 Medical Research Council Recombinant antibodies and methods for their production
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
WO1998013388A1 (en) 1996-09-26 1998-04-02 Chugai Seiyaku Kabushiki Kaisha Antibody against human parathormone related peptides
JP2004147565A (ja) * 2002-10-30 2004-05-27 Japan Science & Technology Agency 不死化ナチュラルキラー細胞株
WO2006067913A1 (ja) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
WO2006067847A1 (ja) 2004-12-22 2006-06-29 Chugai Seiyaku Kabushiki Kaisha フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法

Non-Patent Citations (37)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Immunology", 1993, JOHN WILEY & SONS, INC., article "Immunologic studies in humans"
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 403 - 410
ALTSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402
BLOOD, vol. 101, 2003, pages 4479
BLOOD, vol. 107, 2006, pages 4669
CELL. IMMUNOL., vol. 115, 1988, pages 257
CLEMENCEAU B. ET AL.: "Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes", BLOOD, vol. 107, no. 12, 2006, pages 4669 - 4677, XP002492490 *
DALBADIE-MCFARLAND, G., PROC. NATL. ACAD. SCI. USA, vol. 79, 1982, pages 6409 - 6413
GENE, vol. 108, 1991, pages 193 - 200
GRANTHAM R., NUCLEIC ACIDS RES., vol. 9, 1981, pages R43 - 74
HASHIMOTO-GOTOH, T. ET AL., GENE, vol. 152, 1995, pages 271 - 275
IMMUNITY, vol. 23, 2005, pages 41
IMMUNOL. LETT., vol. 92, 2004, pages 199
J. BIOCHEM., vol. 101, 1987, pages 1307
J. BIOL. CHEM., vol. 279, 2004, pages 53907
J. BIOL. CHEM., vol. 281, 2006, pages 17108
J. IMMUNOL., vol. 146, 1991, pages 1571
KARLIN; ALTSCHUL, PROC. NATL. ACAD. SCI. USA, vol. 87, 1990, pages 2264 - 2268
KRAMER W; FRITZ HJ, METHODS. ENZYMOL., vol. 154, 1987, pages 350 - 367
KRAMER, W. ET AL., NUCLEIC ACIDS RES., vol. 12, 1984, pages 9441 - 9456
KUNKEL, METHODS ENZYMOL., vol. 85, 1988, pages 2763 - 2766
KUNKEL, TA, PROC. NATL. ACAD. SCI. USA., vol. 82, 1985, pages 488 - 492
LEUKEMIA RES., vol. 27, 2003, pages 935
MARK, D. F., PROC. NATL. ACAD. SCI. USA, vol. 81, 1984, pages 5662 - 5666
MED. IMMUNOL., vol. 20, 1990, pages 27 - 32
NATURE, vol. 329, 1987, pages 840
NATURE, vol. 329, 1987, pages 840 - 842
NUCLEIC ACIDS RES., vol. 18, 1990, pages 5322
ONCOL. REP., vol. 15, 2006, pages 361
OSHIMA T. ET AL.: "Pharmacokinetics of S-1 in patients with peritoneal dissemination of gastric cancer", ONCOL. REP., vol. 16, no. 2, 2006, pages 361 - 366, XP008119089 *
PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 5873 - 5877
SCIENCE, vol. 310, 2005, pages 1510
SHAHIED L.S. ET AL.: "Bispecific minibodies targeting HER2/neu and CD16 exhibit improved tumor lysis when placed in a divalent tumor antigen binding format", J. BIOL. CHEM., vol. 279, no. 52, 2004, pages 53907 - 53914, XP008118067 *
WANG, A., SCIENCE, vol. 224, pages 1431 - 1433
WILBUR, W. J.; LIPMAN, D. J., PROC. NATL. ACAD. SCI. USA, vol. 80, 1983, pages 726 - 730
ZOLLER, M. J.; SMITH, M., NUCLEIC ACIDS RESEARCH, vol. 10, 1982, pages 6487 - 6500
ZOLLER, MJ; SMITH, M., METHODS ENZYMOL., vol. 100, 1983, pages 468 - 500

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010074049A1 (ja) 2008-12-22 2010-07-01 株式会社 未来創薬研究所 抗hs6st2抗体及びその用途
WO2010073694A1 (ja) 2008-12-25 2010-07-01 国立大学法人東京大学 抗tm4sf20抗体を用いた癌の診断と治療
WO2010074192A1 (ja) 2008-12-26 2010-07-01 国立大学法人東京大学 抗lgr7抗体を用いる癌の診断および治療
WO2011093097A1 (ja) 2010-01-29 2011-08-04 株式会社未来創薬研究所 抗dll3抗体
EP3342786A1 (en) 2010-01-29 2018-07-04 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
EP3907242A1 (en) 2010-01-29 2021-11-10 Chugai Seiyaku Kabushiki Kaisha Anti-dll3 antibody
WO2012144208A1 (ja) 2011-04-18 2012-10-26 国立大学法人東京大学 抗itm2a抗体を用いる癌の診断および治療
WO2013147153A1 (ja) 2012-03-29 2013-10-03 株式会社未来創薬研究所 抗ｌａｍｐ５抗体およびその利用

Also Published As

Publication number Publication date
EP2123754A1 (en) 2009-11-25
US9733245B2 (en) 2017-08-15
EP2123754A4 (en) 2010-01-27
US20100035280A1 (en) 2010-02-11
JPWO2008093688A1 (ja) 2010-05-20
DE602008006041D1 (de) 2011-05-19
US8946385B2 (en) 2015-02-03
EP2123754B1 (en) 2011-04-06
ATE504647T1 (de) 2011-04-15
US20150079610A1 (en) 2015-03-19
JP5299902B2 (ja) 2013-09-25

Similar Documents

Publication Publication Date Title
ATE504647T1 (de) Chimärer fc gamma rezeptor und verfahren zur bestimmung von adcc-aktivität unter verwendung des rezeptors
WO2009091826A3 (en) Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car)
CY1120707T1 (el) Anti-cd28 εξανθρωπισμενα αντισωματα
EA200970515A1 (ru) МОДИФИЦИРОВАННЫЕ РАСТВОРИМЫЕ СЛИТЫЕ КОНСТРУКЦИИ РЕЦЕПТОРА FGF И Fc С УЛУЧШЕННОЙ БИОЛОГИЧЕСКОЙ АКТИВНОСТЬЮ
WO2009017679A3 (en) Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
GEP20125612B (en) Prlr-specific antibody and usage thereof
WO2011044311A3 (en) Generation, characterization and uses thereof of anti-her 3 antibodies
WO2007110678A3 (en) Neutralizing antibodies and methods of use thereof
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
MX2010007935A (es) Anticuerpo monoclonal humanizado anti-nkg2a humano.
WO2017172981A3 (en) Chimeric antigen receptors targeting cancer
IL211742A (en) Isolated monoclonal antibodies specifically associated with frizzled receptor and various aspects thereof
WO2008045437A3 (en) Chimeric t-cell receptors and t-cells targeting egfrviii on tumors
WO2012103360A3 (en) Wnt compositions and methods of use thereof
UA104587C2 (ru) Моноклональное антитело и способ его применения
WO2010141249A3 (en) Generation, characterization and uses thereof of anti-notch3 antibodies
WO2013033008A3 (en) Tandem fc bispecific antibodies
EP2737907A3 (en) Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease
MY155621A (en) Axl antibodies
WO2013041844A3 (en) Antibodies, variable domains & chains tailored for human use
WO2010042799A3 (en) Novel chimeric ligand-gated ion channels and methods of use thereof
PE20081186A1 (es) Metodos y composiciones para el tratamiento de enfermedades alergicas
UA117801C2 (uk) Лікування неврологічного порушення за допомогою антитіла, яке має низьку афінність до рецептора гематоенцефалічного бар'єру
DK2073842T3 (da) Anvendelse af humane celler af myeloid leukæmioprindelse til ekspression af antistoffer.
WO2007127317A3 (en) Humanized c-kit antibody

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08704115

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2008556119

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008704115

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12525031

Country of ref document: US